New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:52 EDTORAN, SNY, SLBWestern companies may seek return to Iran as sanctions ease, WSJ says
Temporary sanctions relief hasn't yet translated into an economic turnaround in Iran, but a steady flow of executives in recent weeks signals that some companies that previously did business there, such as Schlumberger (SLB), Sanofi (SNY), and Orange (ORAN), may be interested in exploring a return, according to The Wall Street Journal. Reference Link
News For ORAN;SNY;SLB From The Last 14 Days
Check below for free stories on ORAN;SNY;SLB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
16:31 EDTSNYRegeneron, Sanofi announce plan to use priority review voucher for alirocumab
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the companies intend to use a FDA rare pediatric disease priority review voucher in connection with the Biologics License Application, or BLA, submission for alirocumab. The priority review voucher entitles the holder to designate a BLA for priority review, which provides for an expedited 6-month review from the filing date instead of the standard 10-month review. Regeneron Ireland, an indirect, wholly-owned subsidiary of Regeneron Pharmaceuticals, purchased the voucher from BioMarin GALNS, a direct, wholly-owned subsidiary of BioMarin Pharmaceutical (BMRN), which had received it through the FDA's rare pediatric disease priority review voucher program. Sanofi and Regeneron will equally share the purchase price of $67.5M. Sanofi and Regeneron expect to submit U.S. and EU regulatory submissions for alirocumab before year end.
12:33 EDTSNYRegeneron, Sanofi likely to file alirocumab BLA this year, says Piper Jaffray
Subscribe for More Information
08:08 EDTSNYSanofi and Regeneron report positive Phase 2 results of alirocumab
Subscribe for More Information
July 28, 2014
09:02 EDTSNYSanofi, InnerWorkings sign global marketing partnership
Subscribe for More Information
July 21, 2014
08:10 EDTSLBSchlumberger shares should be bought, says BMO Capital
After Schlumberger reported slightly higher than expected operating EPS and said its North American margins had dropped slightly, BMO Capital thinks the company reported good results. The firm expects the stock to perform well going forward and keeps an Outperform rating on the shares.
07:11 EDTSNYInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 18, 2014
08:35 EDTSLBSchlumberger 'bullish' on China although expectations are tempered
08:31 EDTSLBSchlumberger maintains outlook for FY14, due to mix of headwinds and tailwinds
Subscribe for More Information
July 17, 2014
18:31 EDTSLBOn The Fly: After Hours Movers
Subscribe for More Information
16:19 EDTSLBSchlumberger says global economic outlook continues to be mixed
The company said, "the overall global economic outlook continues to be mixed as the US recovery from the effects of the unusually harsh winter coupled with a weaker forecast in Brazil, anemic growth in the Eurozone, and stabilizing GDP in China produce a slightly more cautious short-term GDP growth outlook. The fundamentals for a slow and steady recovery, however, remain intact. On the other hand, the gap between oil supply and demand is tightening on stronger demand and lower non-OPEC supply leading to narrower spare capacity and consequent support for oil prices that modulate customer spend. Natural gas markets on the other hand appear comfortably supplied with little upward pressure on prices. We believe that this outlook will be slow to change and that the scenario for growth that we unveiled at our investor conference in New York last month is highly realistic. The opportunities that new technologies offer in response to customer challenges coupled with greater integration will lead to clearly differentiated financial growth that can only be augmented by the gains that increased reliability and efficiency will provide. In this environment, Schlumberger will continue to outperform.
16:17 EDTSLBSchlumberger reports Q2 EPS ex-items $1.37, consensus $1.36
Subscribe for More Information
15:26 EDTSLBNotable companies reporting after market close
Subscribe for More Information
July 16, 2014
09:03 EDTSNYSanofi held talks on mature drugs with Abbott, Mylan, PE firms, Reuters says
Sanofi (SNY) has shopped an $8.5B portfolio of mature drugs to Abbott (ABT), Mylan (MYL) and private equity firms, according to Reuters, citing an internal company document circulated by the CGT union. Sanofi is considering whether to sell, carve out or create a joint venture for the portfolio of about 200 drugs, but a Sanofi spokesman said no decision has yet been made, the report noted. Reference Link
06:27 EDTSLBSchlumberger July volatility elevated into Q2 and outlook
Subscribe for More Information
06:12 EDTSLBPrecision Drilling announces strategic agreement with Schlumberger
Precision Drilling (PDS) announced it had entered into a strategic technology and service agreement and marketing alliance with Schlumberger (SLB). The agreement aims to increase the industrialization of unconventional drilling in North America through an engineered approach that utilizes Precision's Tier 1 drilling rigs and allows Precision access to Schlumberger's bottomhole assembly and services. The agreement applies to Canada and the Lower 48 states in the U.S. and includes contract drilling services, downhole drilling and measurement technology, engineering expertise and operational training. Through this agreement, Precision will continue to expand its integrated directional drilling services utilizing Schlumberger's downhole tools and related services supported by drilling engineering and modeling, component integration, industry leading subsurface knowledge and expertise, and high-quality measurements.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use